DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at William Blair issued their FY2017 earnings estimates for DexCom in a research note issued to investors on Thursday. William Blair analyst M. Kaczor forecasts that the medical device company will earn ($0.70) per share for the year. William Blair also issued estimates for DexCom’s FY2018 earnings at ($0.74) EPS.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million for the quarter, compared to analyst estimates of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The business’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period last year, the company earned ($0.24) EPS. TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/23/william-blair-weighs-in-on-dexcom-inc-s-fy2017-earnings-dxcm.html.

DXCM has been the topic of several other reports. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Wedbush reiterated a “buy” rating and issued a $76.00 price target on shares of DexCom in a report on Wednesday, October 4th. Robert W. Baird reiterated a “hold” rating and issued a $79.00 price target on shares of DexCom in a report on Sunday, September 10th. Barclays PLC initiated coverage on DexCom in a report on Friday, September 15th. They issued an “equal weight” rating and a $76.00 price target on the stock. Finally, Raymond James Financial, Inc. downgraded DexCom from an “outperform” rating to a “mkt perform” rating in a report on Friday, September 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $72.19.

Shares of DexCom (DXCM) opened at 44.78 on Monday. DexCom has a 12 month low of $42.62 and a 12 month high of $88.80. The stock has a 50 day moving average price of $59.40 and a 200-day moving average price of $69.45. The company’s market capitalization is $3.88 billion.

Hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC lifted its holdings in shares of DexCom by 9.9% during the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after purchasing an additional 978,898 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of DexCom by 101,699.8% during the 2nd quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock valued at $499,522,000 after purchasing an additional 6,822,023 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of DexCom by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock valued at $498,963,000 after purchasing an additional 224,808 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of DexCom by 5.5% during the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock valued at $321,232,000 after purchasing an additional 230,542 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of DexCom by 18.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,948,468 shares of the medical device company’s stock valued at $288,669,000 after purchasing an additional 607,972 shares during the last quarter.

In other DexCom news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $69.77, for a total transaction of $418,620.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total value of $230,907.92. The disclosure for this sale can be found here. Insiders have sold a total of 21,573 shares of company stock worth $1,524,286 in the last ninety days. Insiders own 1.70% of the company’s stock.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.